| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yang Sun, Dana Gallacchi, Erik Y Zhang, Samuel B Reynolds, Lauren Robinson, Izabela A Malinowska, Terry T Chiou, Ana M Pereira, Chenggang Li, David J Kwiatkowski, Po-Shun Lee, Jane J Y. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis. American journal of respiratory cell and molecular biology. vol 51. issue 6. 2015-01-30. PMID:24874429. |
lam cells typically have inactivating tuberous sclerosis complex 2 (tsc2) mutations and mammalian target of rapamycin (mtor) complex (mtorc) 1 activation. |
2015-01-30 |
2023-08-13 |
mouse |
| Han C Dan, Aaron Ebbs, Manolis Pasparakis, Terry Van Dyke, Daniela S Basseres, Albert S Baldwi. Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα). The Journal of biological chemistry. vol 289. issue 36. 2015-01-28. PMID:24990947. |
akt is known to stimulate mtorc1 activity through phosphorylation of tuberous sclerosis complex 2 (tsc2) and pras40, both negative regulators of mtor activity. |
2015-01-28 |
2023-08-13 |
Not clear |
| Jianling Chen, Ian Alberts, Xiaohong L. Dysregulation of the IGF-I/PI3K/AKT/mTOR signaling pathway in autism spectrum disorders. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 35. 2014-12-18. PMID:24662006. |
tuberous sclerosis complex 1 (tsc1) and tsc2 are upstream regulators of mammalian target of rapamycin (mtor) and downstream effectors of the pi3k/akt signaling pathway. |
2014-12-18 |
2023-08-12 |
Not clear |
| Shakeel U R Mir, Steven R Schwarze, Ling Jin, Jinling Zhang, Woodrow Friend, Sumitra Miriyala, Daret St Clair, Rolf J Crave. Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy. Autophagy. vol 9. issue 10. 2014-12-16. PMID:24113030. |
we propose that this disruption of autophagy upon pgrmc1 inhibition increases ampk activation, elevating the levels of tsc1 (tuberous sclerosis complex) and tsc2 and inactivating mtor and rps6kb/p70s6k, causing cleaved map1lc3b levels to increase. |
2014-12-16 |
2023-08-12 |
Not clear |
| Joan Liu, Cheryl Reeves, Zuzanna Michalak, Antonietta Coppola, Beate Diehl, Sanjay M Sisodiya, Maria Tho. Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies. Acta neuropathologica communications. vol 2. 2014-12-08. PMID:25005575. |
activation of the mtor pathway has been linked to the cytopathology and epileptogenicity of malformations, specifically focal cortical dysplasia (fcd) and tuberous sclerosis (tsc). |
2014-12-08 |
2023-08-13 |
Not clear |
| Aiping Ma, Lianmei Wang, Yunzhou Gao, Zai Chang, Haiyong Peng, Ni Zeng, Yao-Song Gui, Xinlun Tian, Xue Li, Baiqiang Cai, Hongbing Zhang, Kai-Feng X. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality. Human molecular genetics. vol 23. issue 3. 2014-10-28. PMID:24129405. |
this is a study on the role of tuberous sclerosis complex1 (tsc1) mutation and mtor activation in endothelial cells during angiogenic and embryonic development. |
2014-10-28 |
2023-08-12 |
mouse |
| Aiping Ma, Lianmei Wang, Yunzhou Gao, Zai Chang, Haiyong Peng, Ni Zeng, Yao-Song Gui, Xinlun Tian, Xue Li, Baiqiang Cai, Hongbing Zhang, Kai-Feng X. Tsc1 deficiency-mediated mTOR hyperactivation in vascular endothelial cells causes angiogenesis defects and embryonic lethality. Human molecular genetics. vol 23. issue 3. 2014-10-28. PMID:24129405. |
we postulated that disruption of normal angiogenic pathways through hyperactive mtor signaling maybe the mechanism that lead to deranged vascular pathogenesis in the tuberous sclerosis complex. |
2014-10-28 |
2023-08-12 |
mouse |
| Marion Cornu, Wolfgang Oppliger, Verena Albert, Aaron M Robitaille, Francesca Trapani, Luca Quagliata, Tobias Fuhrer, Uwe Sauer, Luigi Terracciano, Michael N Hal. Hepatic mTORC1 controls locomotor activity, body temperature, and lipid metabolism through FGF21. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 32. 2014-10-20. PMID:25082895. |
mammalian target of rapamycin (mtor) is a nutrient-activated kinase and central controller of growth and metabolism that is negatively regulated by the tumor suppressor tuberous sclerosis complex 1 (tsc1). |
2014-10-20 |
2023-08-13 |
mouse |
| Mercè Canal, Joan Romaní-Aumedes, Núria Martín-Flores, Víctor Pérez-Fernández, Cristina Malagelad. RTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disorders. Frontiers in cellular neuroscience. vol 8. 2014-10-17. PMID:25324725. |
although the mechanism is not completely understood, rtp801 inactivates mtor and akt via the tuberous sclerosis complex (tsc1/tsc2) in many cellular contexts. |
2014-10-17 |
2023-08-13 |
Not clear |
| F Wang, X Chen, C Li, Q Sun, Y Chen, Y Wang, H Peng, Z Liu, R Chen, K Liu, H Yan, B H Ye, D J Kwiatkowski, H Zhan. Pivotal role of augmented αB-crystallin in tumor development induced by deficient TSC1/2 complex. Oncogene. vol 33. issue 34. 2014-10-15. PMID:24077282. |
tuberous sclerosis complex 1 (tsc1) and tsc2 are suppressors of mechanistic target of rapamycin (mtor). |
2014-10-15 |
2023-08-12 |
mouse |
| D Y Xia, W Li, H R Qian, S Yao, J G Liu, X K Q. Ischemia preconditioning is neuroprotective in a rat cerebral ischemic injury model through autophagy activation and apoptosis inhibition. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 46. issue 7. 2014-10-03. PMID:23903681. |
autophagic activation was mediated by the tuberous sclerosis type 1 (tsc1)-mtor signal pathway as ipc increased tsc1 but decreased mtor phosphorylation. |
2014-10-03 |
2023-08-12 |
rat |
| Sruti Krishna, Jialong Yang, Hongxia Wang, Yurong Qiu, Xiao-Ping Zhon. Role of tumor suppressor TSC1 in regulating antigen-specific primary and memory CD8 T cell responses to bacterial infection. Infection and immunity. vol 82. issue 7. 2014-10-01. PMID:24818661. |
the tuberous sclerosis 1 (tsc1)/tsc2 complex negatively regulates the activity of an mtor-containing multiprotein complex called mtor complex 1. |
2014-10-01 |
2023-08-13 |
Not clear |
| Victoria Tsai, Whitney E Parker, Ksenia A Orlova, Marianna Baybis, Anthony W S Chi, Benjamin D Berg, Jacqueline F Birnbaum, Jacqueline Estevez, Kei Okochi, Harvey B Sarnat, Laura Flores-Sarnat, Eleonora Aronica, Peter B Crin. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cerebral cortex (New York, N.Y. : 1991). vol 24. issue 2. 2014-09-19. PMID:23081885. |
fetal brain mtor signaling activation in tuberous sclerosis complex. |
2014-09-19 |
2023-08-12 |
mouse |
| Victoria Tsai, Whitney E Parker, Ksenia A Orlova, Marianna Baybis, Anthony W S Chi, Benjamin D Berg, Jacqueline F Birnbaum, Jacqueline Estevez, Kei Okochi, Harvey B Sarnat, Laura Flores-Sarnat, Eleonora Aronica, Peter B Crin. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cerebral cortex (New York, N.Y. : 1991). vol 24. issue 2. 2014-09-19. PMID:23081885. |
tuberous sclerosis complex (tsc) is characterized by developmental malformations of the cerebral cortex known as tubers, comprised of cells that exhibit enhanced mammalian target of rapamycin (mtor) signaling. |
2014-09-19 |
2023-08-12 |
mouse |
| Angela Fuchs, Katharina König, Lukas C Heukamp, Jana Fassunke, Jutta Kirfel, Sebastian Huss, Albert J Becker, Reinhard Büttner, Michael Majore. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer. Diagnostic pathology. vol 9. 2014-09-04. PMID:24593867. |
hamartin (tsc1) and tuberin (tsc2), encoded by the tuberous sclerosis complex (tsc) genes, form a tumor-suppressor heterodimer which is implicated in pi3k-akt signaling and acts as a functional inhibitor of the mammalian target of rapamycin (mtor). |
2014-09-04 |
2023-08-12 |
Not clear |
| Ting Zhang, Pengyuan Dai, Dong Cheng, Liang Zhang, Zijiang Chen, Xiaoqian Meng, Fumiao Zhang, Xiaoying Han, Jianwei Liu, Jie Pan, Guiwen Yang, Cong Zhan. Obesity occurring in apolipoprotein E-knockout mice has mild effects on fertility. Reproduction (Cambridge, England). vol 147. issue 2. 2014-08-26. PMID:24196014. |
quantitative pcr analysis demonstrated that at d 100 the expression of cytochromep450 aromatase (cyp19a1), 3β-hydroxysteroid dehydrogenase (hsd3b), mechanistic target of rapamycin (mtor), and nuclear factor-κb (nfkb) decreased significantly, while that of bcl2-associated agonist of cell death (bad) and tuberous sclerosis complex 2 (tsc2) increased significantly in the apoe(-/-) mice. |
2014-08-26 |
2023-08-12 |
mouse |
| Jessica A Burket, Andrew D Benson, Amy H Tang, Stephen I Deutsc. Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders. Brain research bulletin. vol 100. 2014-08-22. PMID:24295733. |
overactivation of the mammalian target of rapamycin (mtor) has been implicated in the pathogenesis of syndromic forms of autism spectrum disorders (asds), such as tuberous sclerosis complex, neurofibromatosis 1, and fragile x syndrome. |
2014-08-22 |
2023-08-12 |
mouse |
| Charlotte Benson, Joanna Vitfell-Rasmussen, Marco Maruzzo, Cyril Fisher, Nina Tunariu, Scott Mitchell, Omar Al-Muderis, Khin Thway, James Larkin, Ian Judso. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer research. vol 34. issue 7. 2014-08-21. PMID:24982384. |
perivascular epithelioid cell tumors (pecomas) are rare tumors driven by tuberous sclerosis complex gene mutations causing up-regulation of mtor. |
2014-08-21 |
2023-08-13 |
Not clear |
| Romina Moavero, Antonella Coniglio, Francesco Garaci, Paolo Curatol. Is mTOR inhibition a systemic treatment for tuberous sclerosis? Italian journal of pediatrics. vol 39. 2014-07-23. PMID:24044547. |
is mtor inhibition a systemic treatment for tuberous sclerosis? |
2014-07-23 |
2023-08-12 |
Not clear |
| Gert Wiegand, Theodor W May, Philipp Ostertag, Rainer Boor, Ulrich Stephani, David Neal Fran. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. vol 17. issue 6. 2014-07-03. PMID:23845174. |
tuberous sclerosis complex (tsc) is an often severe neurodevelopmental disorder caused by overactivation of the mtor pathway due to mutations in either the tsc1 or tsc2 genes. |
2014-07-03 |
2023-08-12 |
Not clear |